The Apex Times
Above the Noise
Business Wire
BusinessReport: Exxon Mobil joins bidders for Shell’s U.S. chemicals assets, a potential shift for XOM’s refining-and-chemicals outlookThe Apex TimesBusinessUPS says its reorganization will lean more heavily on global logistics than domestic parcel operationsThe Apex TimesBusinessGeneral Dynamics shares fall more than the broader market in late-session tradingThe Apex TimesBusinessEli Lilly to buy Merdia Biosciences in a deal valued at up to $2.88 billion, indicating renewed focus on pipeline expansionThe Apex TimesBusinessNvidia hardware momentum meets a new choke point: copper, not cash, HIVE Digital’s Frank Holmes saysThe Apex TimesBusinessBroadcom’s Sept. 2 earnings set up a high-stakes test for its AI narrativeThe Apex TimesBusinessPalantir CEO Alex Karp pushes back on “tokenmaxxing,” pitching real-world AI value over hypeThe Apex TimesBusinessFTC and 22 states sue Amazon, alleging inflated prices in online ads schemeThe Apex TimesBusinessTesla shares rise after investors refocus on long-term autonomous driving potentialThe Apex TimesBusinessTim Cook’s final day as Apple CEO caps a 15-year push into services, wearables and paymentsThe Apex TimesBusinessNetflix announces new original comedy led by Camila Pitanga and Sergio GuizéThe Apex TimesBusinessWall Street stays upbeat on GE Aerospace after the shares outpace the NasdaqThe Apex TimesBusinessReport: Exxon Mobil joins bidders for Shell’s U.S. chemicals assets, a potential shift for XOM’s refining-and-chemicals outlookThe Apex TimesBusinessUPS says its reorganization will lean more heavily on global logistics than domestic parcel operationsThe Apex TimesBusinessGeneral Dynamics shares fall more than the broader market in late-session tradingThe Apex TimesBusinessEli Lilly to buy Merdia Biosciences in a deal valued at up to $2.88 billion, indicating renewed focus on pipeline expansionThe Apex TimesBusinessNvidia hardware momentum meets a new choke point: copper, not cash, HIVE Digital’s Frank Holmes saysThe Apex TimesBusinessBroadcom’s Sept. 2 earnings set up a high-stakes test for its AI narrativeThe Apex TimesBusinessPalantir CEO Alex Karp pushes back on “tokenmaxxing,” pitching real-world AI value over hypeThe Apex TimesBusinessFTC and 22 states sue Amazon, alleging inflated prices in online ads schemeThe Apex TimesBusinessTesla shares rise after investors refocus on long-term autonomous driving potentialThe Apex TimesBusinessTim Cook’s final day as Apple CEO caps a 15-year push into services, wearables and paymentsThe Apex TimesBusinessNetflix announces new original comedy led by Camila Pitanga and Sergio GuizéThe Apex TimesBusinessWall Street stays upbeat on GE Aerospace after the shares outpace the NasdaqThe Apex TimesBusinessReport: Exxon Mobil joins bidders for Shell’s U.S. chemicals assets, a potential shift for XOM’s refining-and-chemicals outlookThe Apex TimesBusinessUPS says its reorganization will lean more heavily on global logistics than domestic parcel operationsThe Apex TimesBusinessGeneral Dynamics shares fall more than the broader market in late-session tradingThe Apex TimesBusinessEli Lilly to buy Merdia Biosciences in a deal valued at up to $2.88 billion, indicating renewed focus on pipeline expansionThe Apex TimesBusinessNvidia hardware momentum meets a new choke point: copper, not cash, HIVE Digital’s Frank Holmes saysThe Apex TimesBusinessBroadcom’s Sept. 2 earnings set up a high-stakes test for its AI narrativeThe Apex TimesBusinessPalantir CEO Alex Karp pushes back on “tokenmaxxing,” pitching real-world AI value over hypeThe Apex TimesBusinessFTC and 22 states sue Amazon, alleging inflated prices in online ads schemeThe Apex TimesBusinessTesla shares rise after investors refocus on long-term autonomous driving potentialThe Apex TimesBusinessTim Cook’s final day as Apple CEO caps a 15-year push into services, wearables and paymentsThe Apex TimesBusinessNetflix announces new original comedy led by Camila Pitanga and Sergio GuizéThe Apex TimesBusinessWall Street stays upbeat on GE Aerospace after the shares outpace the NasdaqThe Apex TimesBusinessReport: Exxon Mobil joins bidders for Shell’s U.S. chemicals assets, a potential shift for XOM’s refining-and-chemicals outlookThe Apex TimesBusinessUPS says its reorganization will lean more heavily on global logistics than domestic parcel operationsThe Apex TimesBusinessGeneral Dynamics shares fall more than the broader market in late-session tradingThe Apex TimesBusinessEli Lilly to buy Merdia Biosciences in a deal valued at up to $2.88 billion, indicating renewed focus on pipeline expansionThe Apex TimesBusinessNvidia hardware momentum meets a new choke point: copper, not cash, HIVE Digital’s Frank Holmes saysThe Apex TimesBusinessBroadcom’s Sept. 2 earnings set up a high-stakes test for its AI narrativeThe Apex TimesBusinessPalantir CEO Alex Karp pushes back on “tokenmaxxing,” pitching real-world AI value over hypeThe Apex TimesBusinessFTC and 22 states sue Amazon, alleging inflated prices in online ads schemeThe Apex TimesBusinessTesla shares rise after investors refocus on long-term autonomous driving potentialThe Apex TimesBusinessTim Cook’s final day as Apple CEO caps a 15-year push into services, wearables and paymentsThe Apex TimesBusinessNetflix announces new original comedy led by Camila Pitanga and Sergio GuizéThe Apex TimesBusinessWall Street stays upbeat on GE Aerospace after the shares outpace the NasdaqThe Apex Times
Back to front
Eli Lilly agrees to buy three vaccine developers as it pushes further into infectious disease
The Apex Times

THE APEX TIMES

Business/The Apex Times/Jun 7, 1:20 AM EDT

Eli Lilly agrees to buy three vaccine developers as it pushes further into infectious disease

The deals total up to nearly $4 billion in cash, adding shingles, bacterial infection and Epstein-Barr virus vaccine platforms to Lilly’s pipeline.

By The Apex Times Newsroom3 min readAI-assisted Apex article

Eli Lilly (NYSE: LLY) said on May 26, 2026 that it has agreed to acquire three vaccine and infectious-disease companies - Curevo, LimmaTech Biologics and Vaccine Company - in transactions that Lilly says could be worth up to nearly $4 billion in cash. The company framed the purchases as a way to deepen infectious-disease research and emphasize prevention strategies, while highlighting long-term risks that can follow common viral and bacterial infections. Lilly investor release

Curevo is developing amezosvatein, an adjuvanted subunit vaccine candidate for shingles in adults. Lilly said a Phase 2 head-to-head study against the existing standard of care showed comparable immune responses across primary endpoints, while reducing side effects such as activity-limiting fatigue, chills and injection-site pain by more than half - an approach Lilly linked to improving real-world vaccine uptake. Lilly indicated Curevo shareholders could receive up to $1.5 billion in cash, including upfront and milestone-based payments. Lilly investor release (PDF)

Lilly also agreed to acquire LimmaTech Biologics, which is focused on bacterial pathogens as antimicrobial resistance narrows treatment options. In its announcement, Lilly described LimmaTech’s platform as designed to generate broad, durable immune responses against complex bacterial targets by targeting toxins and superantigens, and it pointed to a lead program (LTB-SA7) in Phase 1 development for Staphylococcus aureus, a leading cause of surgical-site infection. Lilly said the deal could be worth up to $780 million in cash, including upfront and clinical/regulatory milestone payments. Lilly investor release (PDF)

Vaccine Company is developing proprietary In Vivo Nanoparticle (IVN) technology, which Lilly said is intended to display antigens in a way that can elicit durable immune responses similar to virus-like particle (VLP) vaccines, while avoiding the manufacturing burden of traditional VLP production. Lilly said Vaccine Company’s lead program applies the IVN platform to Epstein-Barr virus (EBV), with a five-antigen candidate described as Phase 1-ready. Lilly said Vaccine Company shareholders could receive up to $1.55 billion in cash, including upfront and clinical/commercial milestone payments. Lilly investor release

Lilly’s scientific rationale centers on the idea that infections can contribute to serious downstream outcomes years later, including neurological disease, cancer and infertility - topics Lilly tied to its view that vaccines are increasingly important as resistance erodes the ability to treat bacterial infections. In that context, Lilly said it is pursuing a prevention-at-the-source strategy rather than focusing only on treating the long-term consequences after infection has occurred. Lilly investor release (PDF)

The company said the transactions are subject to customary closing conditions, including expiration of the waiting period under the Hart-Scott-Rodino (HSR) Act, a U.S. antitrust review process for large deals. Lilly also noted it will determine acquisition accounting under U.S. GAAP after closing and that the deal terms are structured with contingent milestone payments. Lilly did not provide in the announcement a specific expected closing date or a detailed list of milestone thresholds beyond referencing “certain” clinical, regulatory and commercial milestones. Lilly investor release

Why It Matters

  • The purchases announcement that Lilly’s growth strategy is extending beyond its metabolic franchise into infectious-disease prevention, using vaccine platforms to target longer-term complications of infections.
  • By emphasizing tolerability and mechanisms aimed at durable immune responses, Lilly is betting that differentiation in vaccine performance can address adoption barriers and clinical limitations.
  • Because the payments are contingent on clinical, regulatory and commercial milestones, the deals shift some value toward outcomes that Lilly must still demonstrate in trials.
  • Deal timing will likely hinge on regulatory review and closing conditions, particularly U.S. antitrust clearance under HSR.

Sources

Key Facts

  • On May 26, 2026, Eli Lilly agreed to buy Curevo, LimmaTech Biologics and Vaccine Company to expand its infectious-disease R&D.
  • Curevo deal value: up to $1.5 billion in cash, including upfront and milestone-based payments, centered on amezosvatein for shingles.
  • LimmaTech Biologics deal value: up to $780 million in cash, including upfront and milestone-based payments, centered on a Phase 1 vaccine program for Staphylococcus aureus.
  • Vaccine Company deal value: up to $1.55 billion in cash, including upfront and milestone-based payments, centered on an IVN platform for an EBV vaccine candidate described as Phase 1-ready.
  • Lilly said the overall transactions are subject to customary closing conditions, including U.S. Hart-Scott-Rodino antitrust review.
  • The companies’ vaccine candidates were described as investigational; Lilly did not indicate any of the programs were approved products at the time of the announcement.

Healthcare Related

Eli Lilly agrees to buy three vaccine developers as it pushes further into infectious disease | The Apex Times